DermTech, Inc. (DMTKQ)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
DermTech, Inc. (DMTKQ) with AI Score 47/100 (Weak). DermTech, Inc. is a molecular diagnostics company focused on developing and marketing non-invasive genomic tests for melanoma detection. The company filed for Chapter 11 bankruptcy in June 2024. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026DermTech, Inc. (DMTKQ) Healthcare & Pipeline Overview
DermTech, Inc. develops and markets non-invasive genomic tests, primarily the DermTech Melanoma Test (DMT), for melanoma detection. The company's innovative approach aims to improve early diagnosis; however, it filed for Chapter 11 bankruptcy in June 2024, adding significant uncertainty to its future operations and market position.
Investment Thesis
DermTech's innovative non-invasive melanoma detection test (DMT) offers a potential advantage over traditional biopsies, addressing a critical need for early and accurate diagnosis. The company's gross margin stands at 1.8%. However, the company's recent Chapter 11 bankruptcy filing introduces significant uncertainty and risk. The company's high beta of 1.87 suggests high volatility. The company's negative profit margin of -659.6% reflects substantial losses. Investors should carefully consider the implications of the bankruptcy proceedings and the company's ability to restructure and regain financial stability before making any investment decisions. The outcome of the bankruptcy proceedings will be a key determinant of the company's future.
Based on FMP financials and quantitative analysis
Key Highlights
- DermTech Melanoma Test (DMT) offers a non-invasive alternative to traditional biopsies for melanoma detection.
- Gross margin of 1.8% indicates limited profitability prior to bankruptcy filing.
- Filed for Chapter 11 bankruptcy on June 18, 2024, introducing significant financial and operational uncertainty.
- Negative profit margin of -659.6% reflects substantial losses prior to bankruptcy.
- Beta of 1.87 suggests high volatility in stock price.
Competitors & Peers
Strengths
- Innovative non-invasive melanoma detection test.
- Potential to reduce the need for surgical biopsies.
- Technology platform applicable to other dermatological conditions.
- Partnerships with pharmaceutical companies for research and development.
Weaknesses
- Chapter 11 bankruptcy filing.
- Negative profit margin.
- Limited gross margin.
- High beta indicating high stock volatility.
Catalysts
- Outcome of Chapter 11 bankruptcy proceedings and restructuring plan.
- Potential for new partnerships or collaborations to support restructuring efforts.
- Any developments in the company's efforts to develop new diagnostic assays.
- Potential for regulatory approvals for new products or services.
Risks
- Uncertainty related to the bankruptcy proceedings and potential liquidation.
- Loss of key personnel during restructuring.
- Inability to secure financing to support restructuring efforts.
- Competition from other diagnostic companies with more stable financial positions.
- Regulatory hurdles for new diagnostic assays.
Growth Opportunities
- Expansion of DermTech Melanoma Test (DMT) Utilization: Increasing adoption of the DMT among dermatologists and oncologists represents a significant growth opportunity. The market for melanoma diagnostics is expanding, driven by rising skin cancer incidence rates. Successful penetration into a larger segment of the dermatology market could substantially increase revenue, assuming the company can resolve its bankruptcy issues. This expansion relies on demonstrating the test's clinical utility and cost-effectiveness, with a potential market size in the millions of tests annually.
- Development of New Diagnostic Assays: DermTech has the opportunity to leverage its technology platform to develop new diagnostic assays for other dermatological conditions, such as psoriasis and atopic dermatitis. These conditions affect a large patient population, creating a substantial market for innovative diagnostic solutions. Successful development and commercialization of these assays could diversify DermTech's revenue streams and reduce its reliance on melanoma testing. The timeline for this growth opportunity depends on research and development progress, regulatory approvals, and market acceptance.
- Strategic Partnerships with Pharmaceutical Companies: Collaborating with pharmaceutical companies to develop and commercialize companion diagnostics for dermatology drugs presents a valuable growth opportunity. By providing custom gene assays and research services, DermTech can support pharmaceutical partners in their drug development efforts. These partnerships can generate revenue through research contracts, milestone payments, and royalties on sales of companion diagnostics. The timeline for this growth opportunity depends on the progress of pharmaceutical companies' clinical trials and regulatory approvals.
- Geographic Expansion Beyond the United States: Expanding the availability of the DermTech Melanoma Test (DMT) to international markets represents a long-term growth opportunity. Skin cancer is a global health concern, and there is a need for improved diagnostic methods in many countries. Successful expansion into international markets could significantly increase DermTech's revenue and market share. This expansion would require regulatory approvals, distribution agreements, and marketing efforts tailored to each market.
- Integration of Artificial Intelligence and Machine Learning: Utilizing AI and machine learning to enhance the accuracy and efficiency of DermTech's diagnostic tests presents a significant growth opportunity. AI-powered algorithms can analyze genomic data to identify patterns and improve the detection of melanoma and other skin conditions. Integrating AI into DermTech's platform could improve diagnostic accuracy, reduce costs, and enhance the company's competitive advantage. The timeline for this growth opportunity depends on the development and validation of AI algorithms.
Opportunities
- Expansion of DMT utilization among dermatologists and oncologists.
- Development of new diagnostic assays for other dermatological conditions.
- Strategic partnerships with pharmaceutical companies for companion diagnostics.
- Geographic expansion beyond the United States.
Threats
- Competition from other diagnostic companies.
- Regulatory hurdles for new diagnostic assays.
- Uncertainty related to the bankruptcy proceedings.
- Potential loss of key personnel during restructuring.
Competitive Advantages
- Proprietary non-invasive genomic testing technology for melanoma detection.
- Established relationships with pathology and oncology practitioners.
- Research services and technology platform for pharmaceutical companies.
- Intellectual property protection for key diagnostic assays.
About DMTKQ
DermTech, Inc., headquartered in San Diego, California, is a molecular diagnostic company specializing in the development and commercialization of non-invasive genomic tests for skin cancer, particularly melanoma. Founded with the goal of improving early melanoma detection, DermTech has focused on providing alternatives to traditional biopsies. The company's primary product, the DermTech Melanoma Test (DMT), utilizes a non-invasive adhesive patch to collect skin samples, which are then analyzed for specific genetic markers associated with melanoma. This approach aims to reduce the need for surgical biopsies and improve diagnostic accuracy. In addition to the DMT, DermTech offers the DermTech Smart Sticker, a tool designed for easy skin sample collection. The company also provides research services and a technology platform to pharmaceutical companies for use in clinical trials. These services involve developing gene expression assays for various dermatological conditions, including psoriasis, atopic dermatitis, and skin aging, as well as creating custom gene assays to support pharmaceutical partners in their drug development efforts. DermTech sells its products and services primarily to pathology and oncology practitioners. However, on June 18, 2024, DermTech, Inc. and its affiliate filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware, introducing substantial financial and operational challenges.
What They Do
- Develop and market the DermTech Melanoma Test (DMT), a non-invasive genomic test for melanoma detection.
- Offer the DermTech Smart Sticker for easy skin sample collection.
- Provide research services and a technology platform to pharmaceutical companies for clinical trials.
- Develop gene expression assays for dermatological conditions like psoriasis and atopic dermatitis.
- Create custom gene assays to support pharmaceutical partners in their drug development efforts.
- Sell products and services to pathology and oncology practitioners.
Business Model
- Direct sales of the DermTech Melanoma Test (DMT) to healthcare providers.
- Revenue from research services and technology platform provided to pharmaceutical companies.
- Sales of DermTech Smart Stickers for skin sample collection.
- Potential royalties from companion diagnostics developed in partnership with pharmaceutical companies.
Industry Context
DermTech operates within the medical diagnostics industry, which is characterized by technological innovation and increasing demand for early and accurate disease detection. The market for melanoma diagnostics is driven by the rising incidence of skin cancer and the need for less invasive diagnostic methods. DermTech's non-invasive DMT test positions it within a growing segment of the market focused on improving patient outcomes and reducing healthcare costs. However, the industry is competitive, with companies like ABMC, AHPIQ, CRYO, ERUC, and GTHR developing alternative diagnostic solutions. DermTech's recent bankruptcy filing adds a layer of complexity, potentially impacting its ability to compete effectively.
Key Customers
- Pathology practitioners
- Oncology practitioners
- Dermatologists
- Pharmaceutical companies
DMTKQ Financials
DMTKQ Price Today & Live Chart
DermTech, Inc. (DMTKQ) stock price: Price data unavailable
DMTKQ Latest News
No recent news available for DMTKQ.
DMTKQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DMTKQ.
Price Targets
Wall Street price target analysis for DMTKQ.
DMTKQ MoonshotScore
What does this score mean?
The MoonshotScore rates DMTKQ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Burkhard Jansen
CEO
Burkhard Jansen serves as the CEO of DermTech, Inc. His background includes experience in managing and leading teams within the healthcare sector. Information on his specific career history, education, and previous roles is not available in the provided data. He is responsible for overseeing the company's strategic direction and operations.
Track Record: Due to the recent bankruptcy filing, assessing Burkhard Jansen's track record is challenging. Key strategic decisions and company milestones under his leadership are difficult to evaluate given the current financial state of DermTech. The success of the company's restructuring efforts will be a critical factor in determining his long-term impact.
DMTKQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that DermTech, Inc. does not meet the minimum financial standards or reporting requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may be distressed, bankrupt, or unwilling to provide regular financial disclosures. Trading on the OTC Other tier carries significant risks compared to exchanges like the NYSE or NASDAQ, due to less stringent listing requirements and reduced regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Higher potential for fraud and manipulation due to less regulatory oversight.
- Bankruptcy status adds significant uncertainty and risk.
- Low trading volume and wide bid-ask spreads increase volatility.
- Delisting from major exchanges indicates financial distress.
- Verify the company's current financial status and bankruptcy proceedings.
- Review any available financial reports and disclosures.
- Assess the company's restructuring plan and prospects for recovery.
- Evaluate the company's management team and their experience.
- Monitor trading volume and bid-ask spreads for liquidity.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a financial advisor before making any investment decisions.
- Existing intellectual property in melanoma detection.
- Prior partnerships with pharmaceutical companies.
- Continued operation, albeit under bankruptcy protection.
- CEO in place managing 206 employees.
- History of developing and marketing diagnostic tests.
DermTech, Inc. Healthcare Stock: Key Questions Answered
What does DermTech, Inc. do?
DermTech, Inc. is a molecular diagnostic company that develops and markets non-invasive genomic tests for the detection and management of skin cancer, primarily melanoma. Its flagship product, the DermTech Melanoma Test (DMT), uses a non-invasive adhesive patch to collect skin samples for genomic analysis, offering an alternative to traditional surgical biopsies. The company also provides research services and technology platforms to pharmaceutical companies for use in clinical trials. However, the company filed for Chapter 11 bankruptcy in June 2024.
What do analysts say about DMTKQ stock?
AI analysis is pending for DMTKQ. Given the company's Chapter 11 bankruptcy filing, traditional analyst ratings and valuation metrics may not be reliable indicators of future performance. Investors should focus on the company's restructuring plan, its ability to secure financing, and the potential for long-term value creation. The company's high beta suggests significant volatility, and its negative profit margin reflects substantial losses. The outcome of the bankruptcy proceedings will be a key determinant of the company's future prospects.
What are the main risks for DMTKQ?
The primary risk for DMTKQ is the uncertainty surrounding its Chapter 11 bankruptcy proceedings. There is a risk of liquidation if the company is unable to develop a viable restructuring plan. Other risks include competition from established diagnostic companies, regulatory hurdles for new products, and the potential loss of key personnel. The company's high beta indicates significant stock volatility, and its negative profit margin reflects substantial losses. Investors should carefully consider these risks before investing in DMTKQ.
What are the key factors to evaluate for DMTKQ?
DermTech, Inc. (DMTKQ) currently holds an AI score of 47/100, indicating low score. Key strength: Innovative non-invasive melanoma detection test. Primary risk to monitor: Uncertainty related to the bankruptcy proceedings and potential liquidation. This is not financial advice.
How frequently does DMTKQ data refresh on this page?
DMTKQ prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven DMTKQ's recent stock price performance?
Recent price movement in DermTech, Inc. (DMTKQ) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative non-invasive melanoma detection test. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider DMTKQ overvalued or undervalued right now?
Determining whether DermTech, Inc. (DMTKQ) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying DMTKQ?
Before investing in DermTech, Inc. (DMTKQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.
- The company's bankruptcy status introduces significant uncertainty.
- AI analysis is pending.